[1]Benjamin J. Solomon, et al. Updated Efficacy and Safety From the Phase 3 CROWN Study of First-Line Lorlatinib vs Crizotinib in Advanced Anaplastic Lymphoma Kinase (ALK)–Positive Non-Small Cell Lung Cancer (NSCLC). AACR 2022, Abstract #CT223...
近日,新英格兰杂志(NEJM)在线发表了题为:Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer的国际多中心临床试验-ALINA研究,为ALK阳性肺癌定义了新的术后辅助标准治疗。该项研究由广东省人民医院广东省肺癌研究所的吴一龙教授及澳大利亚...
[2]Zhou F, Guo H, Xia Y, et al. The changing treatment landscape of EGFR-mutant non-small-cell lung cancer. Nat Rev Clin Oncol. 2025 Feb;22(2):95-116. [3]Solomon BJ, Liu G, Felip E, et al. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lu...
2024年4月11日，广东省人民医院吴一龙教授及澳大利亚Peter Mac 癌症研究中心Benjamin J. Solomon共同通讯在《New England Journal of Medicine》发表题为《Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer 》的文章，显著提高了该类患者的无病生存率，显示了良好的治疗效益。研究方法 该研究是一项由全球...
5、Soda M, Choi Y L, Enomoto M, et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer[J]. Nature, 2007, 448(7153): 561-566.6、Camidge D R, Bang Y J, Kwak E L, et al. Activity and safety of crizotinib in patients with ALK-positive non-...
希望这个病例能够给其他患者带来希望和启示,让更多人了解和应用这些治疗方法,提高治愈的机会和生存质量。 参考文献: Qi Song, et al., Neoadjuvant immunotherapy plus chemotherapy and adjuvant targeted therapy in ALK-positive non-small-cell lung cancer, Immunotherapy (2023)....
Evaluation of body mass composition (BMC) changes in metastatic ALK-positive non-small cell lung cancer (ALK-mNSCLC) patients treated with anti-ALK tyrosine kinase inhibitors (aALK-TKIs): Preliminary results 评估接受ALK-TKIs治疗的晚期ALK+NSCLC患者的身体成分(BMC)变化: 初步结果 ...
11、Mok T, Camidge D R, Gadgeel S M, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study[J]. Annals of oncology, 2020, 31(8): 1056-1064. ...
2024 年 4 月 18 日,FDA批准阿来替尼(alectinib,Alecensa,Genentech, Inc.)用于间变性淋巴瘤激酶(ALK)阳性非小细胞肺癌(NSCLC)患者肿瘤切除后的辅助治疗。基因泰克公司首席医疗官兼全球产品开发主管Levi …
NON-small-cell lung carcinomaANAPLASTIC lymphoma kinaseCANCER relapseAnaplastic lymphoma kinase (ALK) inhibitors have been shown to be effective in treating patients with ALK-positive non-small cell lung cancer (NSCLC), and crizotinib, ceritinib and alectinib have been approved as clini...